Exploration of Targeted Anti-tumor Therapy

Table 1.

Trials of approved checkpoint inhibitors for R/M HNSCC

Authors	Study	Setting	Study arm	Control arm	Median OS		Approval
Ferris et al. [5]	CheckMate-141	Platinum-resistant	Nivo	SoC	Nivo: 7.5 months SoC: 5.1 months		FDA EMA
Cohen et al. [4]	KEYNOTE-040	Platinum-resistant	Pembro	SoC	Pembro: 8.4 months SoC: 6.9 months		FDA EMA (TPS ≥ 50%)
Burtness et al. [11]	KEYNOTE-048^*	First-line	Pembro	EXTREME	PD-L1 CPS ≥ 20 Pembro: 14.9 months EXTREME: 10.8 months	PD-L1 CPS ≥ 1 Pembro: 12.3 months EXTREME: 10.4 months	FDA EMA
Burtness et al. [11]	KEYNOTE-048^*	First-line	Pembro + CT	EXTREME	PD-L1 CPS ≥ 20 Pembro + CT: 14.7 months EXTREME: 11.1 months	PD-L1 CPS ≥ 1 Pembro + CT: 13.6 months EXTREME: 10.6 months	FDA EMA

ESMO 2020 Congress update